T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
Evolent Health
EVH
$413M
| $538K | ﹤0.01% |
134,413
+18,653
| +16% | +$104K |
|
2352
Stagwell
STGW
$2.01B
| $538K | ﹤0.01% |
109,835
+7,029
| +7% | +$36.6K |
|
2353
World Acceptance Corp
WRLD
$799M
| $538K | ﹤0.01% |
3,826
+213
| +6% | +$32.1K |
|
2354
Columbus McKinnon
CMCO
$473M
| $535K | ﹤0.01% |
30,981
+4,944
| +19% | +$79.3K |
|
|
INN
2355
Summit Hotel Properties
INN
$628M
| $534K | ﹤0.01% |
109,502
+18,790
| +21% | +$98.3K |
|
|
UPB
2356
Upstream Bio Inc
UPB
$290M
| $534K | ﹤0.01% |
19,636
+1,135
| +6% | +$28.3K |
|
2357
RUM Group Inc
RUM
$3.93B
| $533K | ﹤0.01% |
84,317
+9,343
| +12% | +$64.1K |
|
2358
AMC Global Media
AMCX
$496M
| $531K | ﹤0.01% |
55,761
-4,300
| -7% | -$36.2K |
|
2359
Byline Bancorp
BY
$1.68B
| $531K | ﹤0.01% |
18,189
+1,389
| +8% | +$39K |
|
|
RYZ
2360
Ryerson Holding Corp
RYZ
$1.26B
| $528K | ﹤0.01% |
20,985
+1,265
| +6% | +$29.1K |
|
|
GLDD
2361
DELISTED
Great Lakes Dredge & Dock
GLDD
| $526K | ﹤0.01% |
40,082
+5,006
| +14% | +$61.7K |
|
2362
Hertz
HTZ
$602M
| $526K | ﹤0.01% |
102,272
+4,620
| +5% | +$25.2K |
|
2363
Vanguard Morningstar Total Stock Market ETF
VTI
$686B
| $525K | ﹤0.01% |
1,565
| – | – |
|
|
PLYM
2364
DELISTED
Plymouth Industrial REIT
PLYM
| $524K | ﹤0.01% |
23,945
+1,552
| +7% | +$34.1K |
|
2365
Titan International
TWI
$452M
| $524K | ﹤0.01% |
66,800
+3,515
| +6% | +$27.5K |
|
2366
LSB Industries
LXU
$708M
| $520K | ﹤0.01% |
61,102
+3,408
| +6% | +$30.1K |
|
|
RHLD
2367
Resolute Holdings Management
RHLD
$971M
| $520K | ﹤0.01% |
+2,518
| New | +$372K |
|
|
XRN
2368
Chiron Real Estate Inc
XRN
$469M
| $519K | ﹤0.01% |
15,357
+1,849
| +14% | +$60.3K |
|
2369
Tango Therapeutics
TNGX
$4.1B
| $518K | ﹤0.01% |
58,434
+17,765
| +44% | +$153K |
|
2370
Bloomin' Brands
BLMN
$677M
| $517K | ﹤0.01% |
83,764
-6,240
| -7% | -$43.5K |
|
2371
Seaboard Corp
SEB
$3.94B
| $516K | ﹤0.01% |
116
+8
| +7% | +$31.6K |
|
|
DEC
2372
Diversified Energy Company
DEC
$937M
| $515K | ﹤0.01% |
35,502
+2,860
| +9% | +$40.1K |
|
|
MCHB
2373
Mechanics Bancorp
MCHB
$3.3B
| $515K | ﹤0.01% |
35,182
+16,898
| +92% | +$235K |
|
2374
Peapack-Gladstone Financial
PGC
$782M
| $514K | ﹤0.01% |
18,438
+1,710
| +10% | +$46.6K |
|
|
ALH
2375
Alliance Laundry Holdings
ALH
$4.35B
| $513K | ﹤0.01% |
+25,176
| New | +$605K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.